20 January 2021 in Cancer Research
Lung cancer is the leading cause of cancer-related death globally. An improved risk stratification strategy can increase efficiency of low-dose CT (LDCT) screening. Here we assessed whether individual's genetic background has clinical utility for risk stratification in the context of LDCT screening. On the basis of 13,119 patients with lung cancer and 10,008 controls with European ancestry in the International Lung Cancer Consortium, we constructed a polygenic risk score (PRS) via 10-fold cross-validation with regularized penalized regression. The performance of risk model integrating PRS, including calibration and ability to discriminate, was assessed using UK Biobank data (N = 335,931). Absolute risk was estimated on the basis of age-specific lung cancer incidence and all-cause mortality as competing risk. To evaluate its potential clinical utility, the PRS distribution was simulated in the National Lung Screening Trial (N = 50,772 participants). The lung cancer ORs for individuals at the top decile of the PRS distribution versus those at bottom 10% was 2.39 [95% confidence interval (CI) = 1.92–3.00; P = 1.80 × 10−14] in the validation set (Ptrend = 5.26 × 10−20). The OR per SD of PRS increase was 1.26 (95% CI = 1.20–1.32; P = 9.69 × 10−23) for overall lung cancer risk in the validation set. When considering absolute risks, individuals at different PRS deciles showed differential trajectories of 5-year and cumulative absolute risk. The age reaching the LDCT screening recommendation threshold can vary by 4 to 8 years, depending on the individual's genetic background, smoking status, and family history. Collectively, these results suggest that individual's genetic background may inform the optimal lung cancer LDCT screening strategy. Significance: Three large-scale datasets reveal that, after accounting for risk factors, an individual's genetics can affect their lung cancer risk trajectory, thus may inform the optimal timing for LDCT screening.
27 June 2023 in JNCI: Journal of the National Cancer Institute
While lung cancer screening with low-dose computed tomography (LDCT) is rolling out in many areas of the world, differentiating indeterminate pulmonary nodules remains a major challenge. We conducted one of the first systematic investigations of circulating protein markers to differentiate malignant versus benign screen-detected pulmonary nodules. Based on four international LDCT screening studies, we assayed 1078 protein markers using pre-diagnostic blood samples from 1253 participants based on a nested case-control design. Protein markers were measured using proximity extension assays and data were analyzed using multivariable logistic regression, random forest, and penalized regressions. Protein burden scores for overall nodule malignancy (PBS-overall) and imminent tumors (PBS-imminent) were estimated. We identified 36 potentially informative circulating protein markers differentiating malignant from benign nodules, representing a tightly connected biological network. Ten markers were found to be particularly relevant for imminent lung cancer diagnoses within one year. Increases in PBS-overall and PBS-imminent by 1 standard deviation were associated with odds ratios of 2.29(95%CI = 1.95-2.72), and 2.81(95%CI = 2.27-3.54) for nodule malignancy overall, and within 1 year of diagnosis, respectively. Both PBS-overall and PBS-imminent were substantially higher for those with malignant nodules compared to those with benign nodules even when limited to LungRADS category 4 (p < 0.001). Circulating protein markers can help to differentiate malignant from benign pulmonary nodules. Validation with an independent CT-screening study will be required prior to clinical implementation.
18 October 2024 in Cancer Epidemiology, Biomarkers & Prevention
Background: Improvements in cancer control have led to a drastic increase in cancer survivors who may be at an elevated risk of developing subsequent primary cancers (SPC). In this study, we assessed the risk and patterns of SPC development among 196,858 adult cancer survivors in Alberta, Canada. Methods: We used data from the Alberta Cancer Registry to identify all first primary cancers occurring between 2004 and 2020. A SPC was considered as the next primary cancer occurring in a different site. We estimated standardized incidence ratios (SIR) for SPC development as the observed number of SPC (O) divided by the expected number of SPC (E), in which E is a weighted sum of the population-based year–age–sex–specific incidence rates and the corresponding person-years of follow-up. Results: The risk of developing a SPC up to 15 years after an initial cancer was 16.2% for males and 12.2% for females. Overall, both males (SIR = 1.50) and females (SIR = 1.58) had an increased risk of a SPC. There were significant increases in SPC risk for nearly all age groups, with a greater than five-fold increase for survivors diagnosed between ages 18 and 39. Screen-detectable cancers including colorectal, lung, cervix, and breast accounted for 46% and 27% of SPC among females and males, respectively. Conclusions: Cancer survivors of nearly every initial site had substantially increased risk of a SPC, compared with the cancer risk in the general population. Impact: Screen-detectable cancers were common SPC sites and highlight the need to investigate optimal strategies for screening the growing population of cancer survivors.
9 September 2022 in JNCI: Journal of the National Cancer Institute
Background: Lung cancer is the leading cause of cancer mortality globally. Early detection through risk-based screening can markedly improve prognosis. However, most risk models were developed in North American cohorts of smokers, whereas less is known about risk profiles for never-smokers, which represent a growing proportion of lung cancers, particularly in Asian populations.Methods: Based on the China Kadoorie Biobank, a population-based prospective cohort of 512 639 adults with up to 12 years of follow-up, we built Asian Lung Cancer Absolute Risk Models (ALARM) for lung cancer mortality using flexible parametric survival models, separately for never and ever-smokers, accounting for competing risks of mortality. Model performance was evaluated in a 25% hold-out test set using the time-dependent area under the curve and by comparing model-predicted and observed risks for calibration.Results: Predictors assessed in the never-smoker lung cancer mortality model were demographics, body mass index, lung function, history of emphysema or bronchitis, personal or family history of cancer, passive smoking, and indoor air pollution. The ever-smoker model additionally assessed smoking history. The 5-year areas under the curve in the test set were 0.77 (95% confidence interval = 0.73 to 0.80) and 0.81 (95% confidence interval = 0.79 to 0.84) for ALARM-never-smokers and ALARM-ever smokers, respectively. The maximum 5-year risk for never and ever-smokers was 2.6% and 12.7%, respectively.Conclusions: This study is among the first to develop risk models specifically for Asian populations separately for never and ever-smokers. Our models accurately identify Asians at high risk of lung cancer death and may identify those with risks exceeding common eligibility thresholds who may benefit from screening.
1 July 2025 in JCO Oncology Advances
PURPOSE: The vast majority of cervical cancer is preventable through human papillomavirus vaccination and screening with cytology or DNA testing. After decades of progress, recent cervical cancer trends in Western populations show a plateau or modest increase in incidence rates. Further investigation is required to understand the drivers of these emerging trends. In this study, we examined age-specific cervical cancer incidence rates in Canada from 1992 to 2022. METHODS: Data were obtained from the Canadian Cancer Registry maintained by Statistics Canada, which included cancer cases, population counts, and incidence rates of cervical cancer by age and province for the period 1992 to 2022. Joinpoint regression analysis was used to estimate temporal incidence trends across age groups. RESULTS: Cervical cancer incidence rates in Canada decreased among women age 25-34 years and those 65 years and older since 1992. Incidence rates among women age 35-44 years and 45-54 years have increased by 1.1% (95% CI, 0.5 to 2.5) and 1.6% (95% CI, –0.1 to 8.6) per year since 2001 and 2012, respectively. In 2022, the highest incidence rate of cervical cancer was among women age 35-44 years (18.1 per 100,000 women), which is comparable with rates in 1992. CONCLUSION: Cervical cancer incidence rates have been increasing in recent years among women age 35-54 years. This cohort may be falling into a cancer prevention gap. Targeted public health interventions are warranted to address the rising incidence of cervical cancer among this cohort of Canadian women.